Compare Orchid Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CADILA HEALTHCARE - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CADILA HEALTHCARE ORCHID PHARMA LTD/
CADILA HEALTHCARE
 
P/E (TTM) x -0.4 30.1 - View Chart
P/BV x 0.1 3.6 3.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ORCHID PHARMA LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CADILA HEALTHCARE
Mar-19
ORCHID PHARMA LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs194432 44.9%   
Low Rs35306 11.4%   
Sales per share (Unadj.) Rs276.5128.6 215.0%  
Earnings per share (Unadj.) Rs-79.218.5 -427.1%  
Cash flow per share (Unadj.) Rs-43.524.4 -178.1%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9101.5 53.2%  
Shares outstanding (eoy) m70.451,023.74 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.9 14.4%   
Avg P/E ratio x-1.419.9 -7.3%  
P/CF ratio (eoy) x-2.615.1 -17.4%  
Price / Book Value ratio x2.13.6 58.3%  
Dividend payout %018.9 0.0%   
Avg Mkt Cap Rs m8,067378,170 2.1%   
No. of employees `0002.812.4 22.5%   
Total wages/salary Rs m2,52721,241 11.9%   
Avg. sales/employee Rs Th6,956.110,585.0 65.7%   
Avg. wages/employee Rs Th902.51,707.8 52.8%   
Avg. net profit/employee Rs Th-1,993.01,526.5 -130.6%   
INCOME DATA
Net Sales Rs m19,477131,656 14.8%  
Other income Rs m4072,011 20.2%   
Total revenues Rs m19,884133,667 14.9%   
Gross profit Rs m1,10329,731 3.7%  
Depreciation Rs m2,5195,986 42.1%   
Interest Rs m5,2271,935 270.1%   
Profit before tax Rs m-6,23623,821 -26.2%   
Minority Interest Rs m20469 4.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,303 -2.4%   
Profit after tax Rs m-5,58018,987 -29.4%  
Gross profit margin %5.722.6 25.1%  
Effective tax rate %2.022.3 9.0%   
Net profit margin %-28.714.4 -198.7%  
BALANCE SHEET DATA
Current assets Rs m11,01484,981 13.0%   
Current liabilities Rs m32,06073,425 43.7%   
Net working cap to sales %-108.18.8 -1,231.1%  
Current ratio x0.31.2 29.7%  
Inventory Days Days9575 127.3%  
Debtors Days Days34110 30.6%  
Net fixed assets Rs m29,440133,493 22.1%   
Share capital Rs m7051,024 68.8%   
"Free" reserves Rs m2,043102,839 2.0%   
Net worth Rs m3,800103,863 3.7%   
Long term debt Rs m9,01839,497 22.8%   
Total assets Rs m46,510234,831 19.8%  
Interest coverage x-0.213.3 -1.5%   
Debt to equity ratio x2.40.4 624.1%  
Sales to assets ratio x0.40.6 74.7%   
Return on assets %-0.88.9 -8.5%  
Return on equity %-146.918.3 -803.3%  
Return on capital %-3.718.3 -20.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51348,404 15.5%   
Fx outflow Rs m5,64911,593 48.7%   
Net fx Rs m1,86536,811 5.1%   
CASH FLOW
From Operations Rs m1,68228,823 5.8%  
From Investments Rs m-9,860-57,387 17.2%  
From Financial Activity Rs m6,64418,846 35.3%  
Net Cashflow Rs m-1,535-7,105 21.6%  

Share Holding

Indian Promoters % 32.3 74.8 43.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.3 55.4%  
FIIs % 3.3 5.9 55.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 11.0 502.7%  
Shareholders   84,811 44,069 192.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Power and Energy Stocks Drag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is down 0.3%. The Nikkei 225 is trading down by 0.6%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS